doi: 10.1210/er.2013-1083 5 ErnstFRBarrPElmorRSandulliWThevathasanLStermanABet al
A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment
The short needles included with GLP-1 pens are made for subcutaneous injection and usually enter at a 90-degree angle
In addition to its use in weight loss, Semaglutide has also been approved to treat type 2 diabetes
Some state-based marketplace plans do include GLP-1 coverage
Understanding the factors that influence an individuals response, such as baseline BMI, sex, and comorbidities, will be crucial in guiding the selection of the most appropriate treatment approach